Invention Grant
US07862813B2 Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
有权
双特异性单克隆抗体（特异于CD3和CD11b）治疗药物
- Patent Title: Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
- Patent Title (中): 双特异性单克隆抗体（特异于CD3和CD11b）治疗药物
-
Application No.: US11821127Application Date: 2007-06-22
-
Publication No.: US07862813B2Publication Date: 2011-01-04
- Inventor: Robert Lamar Bjork, Jr.
- Applicant: Robert Lamar Bjork, Jr.
- Agency: DLA Piper LLP (US)
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61K51/00 ; A61P43/00 ; C07K14/00 ; G01N33/53 ; C12N5/00
Abstract:
The present invention relates to the treatment of immune system abnormalities that can be found in lethal human cancers and also in the progressive Human Immunodeficiency Virus Type 1 (HIV-1) infections and provides medicaments to correct abnormalities in a subject with cancer or HIV-1-infected subjects, in order to allow the immune system to fight the cancer or HIV-1 infections. The present invention also discloses multivalent polypeptides which specifically bind to and enable destruction and/or inactivation of immune cells that have CD11b and CD3 on their surface, therefore dissipating the deleterious effects of the CD11b+ T cells.
Public/Granted literature
- US20080025914A1 Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug Public/Granted day:2008-01-31
Information query
IPC分类:
